Dry Eye relief your MGD patients can feel and see in HD

 

12 minutes or less.1,2

12 months results.3

Did you know meibomian gland procedures are the fastest growing part of the Dry Eye market?⁴

-44M adults suffer from Dry Eye symptoms in the U.S.4
86% of Dry Eye patients have signs of Meibomian Gland Dysfunction (MGD).5
$3.8B Estimated annual economic burden of Dry Eye for the U.S. healthcare system is $3.8 billion.6
8/10 doctors strongly agree that "Treating Dry Eye patients can help my practice grow."7*

Systane® iLux delivers fast treatment1,2* while allowing patients to visualize their procedure

8-12 minutes stopwatch icon

Intuitive User Experience with rapid treatment

Total treatment in as little as 8 minutes.1,2*

patient receiving Systane iLux MGD treatment

You’re always in control

Customize heat and compression across each easy-to-visualize treatment zone.

Systane iLux MGD treatment device interface

Treatment and education tool

Imaging that can be used for meibography and HD imaging show patients a reason to believe in the value of Meibomian Gland Dysfunction treatment.

*Treatment of both eyes using the Systane® iLux takes approximately 8-12 minutes. 

Dry Eye patients see the value through imaging that can be used for meibography and HD video

Meibography of a patient
alcon-iLux2 dry eye treatment machine expressing clogged meibomian glands

Does your current MGD care regimen yield this level of performance?


7 DAYS
1-week post-treatment Meibomian Gland Score (MGS) increased on average by 315% vs. baseline.⁸**

 

 

**(P<0.0001). In a prospective, open-label, multicenter study of patients ≥18 years with MGD (n=30).

 

Patient with blocked meibomian glands observing her dry eyes

Non-inferiority over 12 Months3 with Systane® iLux®

    Meibomian Gland Score

    Systane® iLux® was demonstrated to be non-inferior to Lipiflow^ for meibomian gland function through 12 months (at all measurements, including 1, 3, 6, 9 months).

    Graph showing Systane iLux was demonstrated to be non-inferior to Lipiflow^ for meibomian gland function through 12 months (at all measurements, including 1, 3, 6, 9 months)


     †Meibomian gland scores (0-45) measured using Meibomian Gland Evaluator to assess the 15 glands of the lower lid of each eye with a grade from 0-3.
    ††Impact of dry eye on every day life (IDEEL - SB) symptom bother score  (with 20 questions).
    ^Trademarks are the property of their respective owners.

    IDEEL-SB Score††

    Systane® iLux® was demonstrated to be non-inferior to LipiFlow^ in reducing symptoms of ocular dryness at 1, 3, 6, 9 and 12 months.

    Graph showing Systane iLux was demonstrated to be non-inferior to LipiFlow^ in reducing symptoms of ocular dryness at 1, 3, 6, 9 and 12 months


    Meibomian gland scores (0-45) measured using Meibomian Gland Evaluator to assess the 15 glands of the lower lid of each eye with a grade from 0-3.
    ††Impact of dry eye on every day life (IDEEL - SB) symptom bother score (with 20 questions).
    ^Trademarks are the property of their respective owners.

    Key Results

    Non-inferiority of iLux® to LipiFlow^ was demonstrated in change from Baseline MGD scores(95% LCL of the LSM difference >-0.5), and change in Baseline IDEEL-SB module score (95% UCL of the LSM difference <12)

    Connected squares representing a prospective, randomized, parallel group icon

    Prospective, randomized, parallel group, investigator-masked, multi-center 12-month follow-up study

    Calendar icon

    Follow-up visits at 2 weeks and 1, 3, 6, 9, and 12 months

    Eye care provider icon

    236 subjects with meibomian gland dysfunction


    Meibomian gland scores (0-45) measured using Meibomian Gland Evaluator to assess the 15 glands of the lower lid of each eye with a grade from 0-3.
    ††Impact of dry eye on every day life (IDEEL - SB) symptom bother score (with 20 questions).
    ^Trademarks are the property of their respective owners.

    Make a Plan with the Systane® iLux2® toolkit

    Dry Eye Excellence Program (DEEP) icon

    Complimentary practice support

    Gain best-in-class Dry Eye management, as well as the practice and patient interaction tools needed for success.

    Systane® My Eyes Program

    Helps drive patient retention

    Year-round support for your patients, throughout their Dry Eye journey, reminds them to come back to your office for further care.

    The Systane® Plan

    Increase patient engagement

    A new Alcon patient engagement program will help patients get started in understanding their Dry Eye symptoms and how to manage it with you and Systane®.

    When Dry Eye patients look to you for relief, make every look count.


    Look to the world’s first and only Meibomian Gland Dysfunction (MGD) Thermal Pulsation System with imaging that can be used for meibography + gland treatment + HD video replay, all in the palm of your hand.

    Dry Eye devices brought to you by Alcon, your end-to-end partner for ocular health

    Blephex eyelid cleaning device for bacterial biofilm

    BlephEx® is the first in-office procedure shown to remove lid debris and bacterial biofilm from eyelids in just 6-8 minutes.9-11

    LashCam device for meibomian glands and eyelid margin images

    LashCam iR™ handheld camera with both blue and white light functionality allows you to visualize the lid margin and the meibomian glands, which helps patients better understand their condition, highlighting the need for treatment.

    CONTINUE YOUR PATIENTS' DRY EYE CARE WITH SYSTANE®, THE #1 DOCTOR RECOMMENDED BRAND OF ARTIFICIAL TEARS¹²

    *vs. SYSTANE® BALANCE.

    Systane Complete and Systane Ultra artificial tears for dry eye treatment

    IMPORTANT PRODUCT INFORMATION
    Systane
    ®
     iLux2®

     

    Indication:
    The Systane® iLux2® is indicated for the application of localized heat and pressure therapy in adult patients with meibomian gland dysfunction (MGD), which is associated with evaporative dry eye, and to capture/store digital images and video of the meibomian glands. 

     

    Contraindications: 
    Do NOT use the Systane® iLux2® in patients with the following conditions:  Patients whose pupils have been pharmaceutically dilated; patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior 3 months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids. 

     

    Warnings/Precautions: 
    Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner. 

     

    The Disposable may not fit all eyes, such as eyes with small palpebral fornices.  Use of the Systane® iLux2® is NOT recommended in patients with the following conditions: moderate to severe allergic, vernal or giant papillary conjunctivitis; severe eyelid inflammation; systemic disease conditions that cause dry eye; in patients who are taking medications known to cause dryness; patients with punctal plugs, or patients who have undergone ocular surgery within prior 3 months. 

     

    Potential Adverse Reactions: 
    Potential adverse effects may occur because of the procedure.  These effects include but are not limited to, the onset or increase in: eyelid/eye pain requiring discontinuation of the treatment procedure, eyelid irritation or inflammation, temporary reddening of the skin, ocular surface irritation or inflammation (e.g., corneal abrasion, conjunctival edema or conjunctival injection (hyperemia)), and ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light). 

     

    Attention: Please refer to the User Manual for a complete list of contraindications, instructions for use, warnings and precautions for the Systane® iLux2®.


    IMPORTANT PRODUCT INFORMATION
    BlephEx
    ®

     

    Indication:
    BlephEx® is intended for exfoliation and debridement of the eyelid margin, from the lash line back to the orifices of the meibomian glands.

     

    Warnings/Precautions:
    Federal law restricts this device to sale by or on the order of a Physician or Optometrist. Only ophthalmologists, optometrists, and their trained staff are authorized to use the device. Failure to follow operating instructions could result in serious injury, including (but not limited to) injury of an eye. Avoid direct, prolonged contact with the eyeball and palpebral conjunctiva. Instill numbing drops into both of your patient’s eyes prior to use.

     

    Attention: Please refer to the User Manual for a complete list of safety instructions and instructions for use for BlephEx®.

     

    References: 1. Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. Clin Ophthalmol. 2020;14:405-418. 2. Alcon data on file, 2019. 3. Alcon data on file, 2021. 4. MarketScope LLC. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. St. Louis, MO: MarketScope LLC; 2020. 5. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472-478. 6. TFOS. TFOS DEWS II. Available at http://www.tearfilm.org/dettreports-tfos dew_ii_report/32_30/eng/. Accessed May 9, 2018. 7. Alcon data on file, 2018. 8. Geffen D, Yeh TN, Merchea MM. iLUX® efficacy after one week of treatment. Poster presented at: American Academy of Optometry 2020 Annual Meeting—Academy 2020 At Home; October 7–22, 2020; Nashville, TN. 9. Siddireddy JS, Vijay AK, Tan J, Willcox M. Effect of Eyelid Treatments on Bacterial Load and Lipase Activity in Relation to Contact Lens Discomfort. Eye Contact Lens. 2020;46(4):245-253. 10. Connor CG, Choat C, Narayanan S, et al. Clinical Effectivenes of Lid Debridement with BlephEx Treatment. IOVS. 2015 June. 56:4440. 11. Choi MB, Stein R. Lid Hygiene Versus Lid Hygiene Plus Microblepharoexfoliation for the Treatment of Demodex folliculorum Blepharitis. Acta Scientific Ophthalmology. 2020:3(9): 29-35. 12. Alcon data on file, 2020.